Payment overview · 2025
General Payments
$18,441.04
192 reported records · 24 companies
Healthcare provider profile · identity verified
Pierre Istfan, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · BRISTOL, TN · NPI 1679518989
Verified facts
What the public records show
CMS Open Payments records show Pierre Istfan, MD received $18,441.04 in general payments during 2025 across 192 reported records.
Medtronic, Inc. accounted for 45.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Brilinta by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 348 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$8,425.23 | 45.7% | 23 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $2,582.00 | 14.0% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $1,890.54 | 10.2% | 57 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $1,692.20 | 9.2% | 7 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $418.71 | 2.3% | 11 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $403.54 | 2.2% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $343.22 | 1.9% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $339.46 | 1.8% | 13 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $323.72 | 1.8% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $320.38 | 1.7% | 15 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $299.35 | 1.6% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $294.62 | 1.6% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $240.45 | 1.3% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $229.83 | 1.2% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $225.68 | 1.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.78 | 0.4% | 5 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $71.60 | 0.4% | 1 | 2025 |
| AtriCure, Inc. | Unresolved — no canonical attribution shown | $65.58 | 0.4% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.24 | 0.3% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $49.74 | 0.3% | 3 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $26.45 | 0.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $24.78 | 0.1% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $22.48 | 0.1% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $19.46 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $8,821.44 | 13 |
| Food and Beverage | $8,119.60 | 178 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $2,582.00 | 11 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1,692.20 | 7 | 2025 |
Source payment records
|
|||||
| ULTREON Normalized: ultreon |
Device | Abbott Laboratories | $581.12 | 16 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $466.75 | 3 | 2025 |
Source payment records
|
|||||
| COROFLOW Normalized: coroflow |
Device | Abbott Laboratories | $419.88 | 13 | 2025 |
Source payment records
|
|||||
| OPTOWIRE Normalized: optowire |
Device | CARDIVA MEDICAL, INC. | $418.71 | 11 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $403.54 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $339.46 | 13 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $320.38 | 15 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $318.68 | 3 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $275.43 | 14 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $240.45 | 8 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $172.87 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $172.87 | 2 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $170.35 | 2 | 2025 |
Source payment records
|
|||||
| IV Other Normalized: iv other |
Device | Philips North America LLC | $168.94 | 3 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $167.52 | 3 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $154.04 | 7 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $144.16 | 1 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $141.97 | 1 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $135.81 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $125.09 | 3 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| VALIANT CAPTIVIA Normalized: valiant captivia |
Device | Medtronic, Inc. | $122.68 | 1 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $121.60 | 2 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $116.49 | 1 | 2025 |
Source payment records
|
|||||
| AFX2 Bifurcated Endograft System Normalized: afx2 bifurcated endograft system |
Device | Endologix LLC | $89.87 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $79.78 | 5 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $79.43 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.24 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $49.74 | 3 | 2025 |
Source payment records
|
|||||
| ATRICLIP LAA EXCLUSION SYSTEM Normalized: atriclip laa exclusion system |
Device | AtriCure, Inc. | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| SYNERGY ABLATION SYSTEM Normalized: synergy ablation system |
Device | AtriCure, Inc. | $49.20 | 3 | 2025 |
Source payment records
|
|||||
| ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM Normalized: atricure cryoice cryosphere cryoablation system |
Device | AtriCure, Inc. | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX Normalized: epi sense guided coagulation system with visitrax |
Device | AtriCure, Inc. | $33.21 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| VSI Normalized: vsi |
Device | Teleflex LLC | $22.48 | 1 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| Omniwire Normalized: omniwire |
Device | Philips North America LLC | $13.92 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $6.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 348 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
348 | 66 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
348 | 66 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 665 | 212 |
| Eliquis | Apixaban | 348 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 271 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 249 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 229 | 70 |
| Xarelto | Rivaroxaban | 208 | 46 |
| Verapamil Er | Verapamil Hcl | 151 | 43 |
| Warfarin Sodium | Warfarin Sodium | 134 | 23 |
| Carvedilol | Carvedilol | 130 | 43 |
| Losartan Potassium | Losartan Potassium | 123 | 33 |
| Cilostazol | Cilostazol | 112 | 40 |
| Lisinopril | Lisinopril | 97 | 27 |
| Atenolol | Atenolol | 85 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 22 |
| Repatha Syringe | Evolocumab | 55 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 53 | 18 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Brilinta | Ticagrelor | 48 | 14 |
| Prasugrel Hcl | Prasugrel Hcl | 42 | suppressed |
| Furosemide | Furosemide | 41 | 13 |
| Spironolactone | Spironolactone | 40 | 15 |
| Nitroglycerin | Nitroglycerin | 39 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 31 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 15 | suppressed |
| Simvastatin | Simvastatin | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $18,441.04 · 192 records | Medtronic, Inc. | AFX2 Bifurcated Endograft System, AMPLATZER TALISMAN, ATRICLIP LAA EXCLUSION SYSTEM, ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM, AVVIGO Guidance System, Alto Abdominal Stent Graft System, CAMZYOS, CARDIOMEMS, COROFLOW, CT THROMBECTOMY SYSTEM KIT, Coronary Other, DRAGONFLY OPSTAR, ELIQUIS, ELUVIA, ENDURANT IIS, EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX, ESPRIT, FARXIGA, FLOWTRIEVER CATHETER, S, General - Therapies, INJECTAFER, IV Other, Indigo System, Kerendia, LEQVIO, LIMFLOW SYSTEM, LOKELMA, LifeVest, OPSUMIT, OPSYNVI, OPTIS, OPTOWIRE, Omniwire, REPATHA, ROTAPRO, RotarexS 6 F x 135 cm, SYMPLICITY G3, SYNERGY ABLATION SYSTEM, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, ULTREON, UPTRAVI, VALIANT CAPTIVIA, VSI, WAINUA, XIENCE SKYPOINT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error